Two small clips on the ear, a handheld device and treatment at home: it is easy to see why this idea would appeal to someone whose blood pressure stays high despite medication. The first results, however, do not amount to proof that an ear clip can reliably bring it down.
Fresh coverage published by ScienceDaily on 24 October revisits the SCRATCH-HTN trial led by Queen Mary University of London. The university released the findings in late September. We are looking at that research again, rather than describing a treatment launched this weekend.
The study involved 63 people with uncontrolled hypertension who were already taking one or more blood pressure medicines. Overall, active treatment did not produce a statistically significant improvement over the comparison device. A more encouraging result appeared in a planned subgroup with more severe hypertension.
For patients, that leaves an interesting technology to follow. It does not provide a reason to stop prescribed treatment or buy an electrical gadget on the assumption that the benefit has been established.
The ear is an access point to a nerve network
The technique is called transcutaneous autonomic neuromodulation, shortened to tAN. The aim is to influence the autonomic nervous system, which helps regulate functions such as blood pressure without us consciously controlling them.
The device developed by Afferent Medical Solutions delivers gentle electrical stimulation through clips attached to the tragus, the small flap of cartilage in front of the ear canal. It is a physical medical-device approach, rather than an AI diagnosis or a phone app estimating a health score.
Participants used either an active or a sham device. Their schedule was 30 minutes a day for the first two weeks, followed by a weekly session for another ten weeks. Researchers found the treatment acceptable and generally well tolerated, with good adherence to the routine.
Those findings answer a practical question: can people use the equipment as planned? They do not, on their own, answer the separate question of whether it lowers blood pressure better than the comparison treatment.
Why the comparison device matters
The trial’s participant information sheet describes a blinded study: participants and the clinical study team would not know which treatment had been allocated. It also explains a planned two-to-one allocation between active and inactive devices.
That design helps researchers separate the effect of the stimulation from the wider experience of joining a study. Regular contact, attention to medication and changes in how a condition is measured can complicate a simple before-and-after comparison.
The information sheet set out clinic assessments including blood pressure monitoring, medication review and questionnaires. It was a supervised research programme, not simply a product sent home with an instruction to try it and report whether the user felt better.
This matters because a health gadget can feel useful without demonstrating the outcome it is supposed to produce. A good trial needs to test the claimed benefit against an appropriate comparison, rather than rely on how convincing the equipment looks.
A subgroup finding is a lead to investigate
The researchers had specified the severe-hypertension subgroup analysis before examining the results. That is more informative than selecting an apparently successful group only after looking through the data.
Even so, a subgroup result in a small trial needs confirmation. It cannot erase the finding that the overall comparison did not show a significant benefit. Chief investigator Ajay Gupta and the university describe larger studies as the next step towards working out which patients, if any, benefit most.
A future trial would need to test the effect in an appropriately selected group and establish how dependable and lasting it is. Patients would also need a clear account of suitability, safety and how the device fits alongside existing care.
No Malaysian availability or approval for this blood-pressure use is established by the sources reviewed. Nor do they provide a Malaysian treatment price. A product advertised online with a similar-looking clip should not be assumed to be the device or treatment tested here.
Monitoring at home is a different job
There is already a useful role for home technology in blood pressure care: measuring it accurately. A monitor records pressure; the experimental ear device attempts to influence it. The two functions should not be confused.
University Hospitals Birmingham’s patient guidance recommends a clinically validated upper-arm monitor and a cuff that fits the user. The point of validation is to establish that the readings can be trusted. A screen displaying numbers is not itself evidence of accuracy.
The NHS’s home-measurement guidance advises sitting in a chair with back support, keeping feet flat and supporting the arm. The cuff should be placed over a bare arm, with the person relaxed and not talking during the measurement. A second reading helps check the result.
For someone sharing readings with a clinician, keeping the measurement conditions consistent makes the record more useful. Ask your own healthcare team how often to measure and how they want the results recorded, rather than changing the schedule because of a device headline.
What patients can use now
NHS guidance notes that hypertension often has no symptoms. Feeling well therefore does not establish that pressure is controlled. The value of a check is that it can reveal a problem that would otherwise go unnoticed.
Its patient information also explains that treatment can combine lifestyle changes with medication, sometimes more than one medicine. MyHealth London’s guidance stresses taking prescribed medication regularly and discussing side effects or changes with the healthcare team. Targets and treatment choices need to fit the individual.
For Malaysian readers already managing hypertension, the useful conversation today is about reliable readings, treatment adherence and a review if control remains poor. The ear-stimulation research may eventually add another option. The evidence still has to show who it helps, how much it helps and whether that benefit holds up in a larger trial.
Sources & further reading
Prepared with AI assistance from linked reporting. The cover is an AI-generated editorial illustration. Spotted something we should correct?